These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30094053)

  • 21. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    Iveson TJ; Kerr RS; Saunders MP; Cassidy J; Hollander NH; Tabernero J; Haydon A; Glimelius B; Harkin A; Allan K; McQueen J; Scudder C; Boyd KA; Briggs A; Waterston A; Medley L; Wilson C; Ellis R; Essapen S; Dhadda AS; Harrison M; Falk S; Raouf S; Rees C; Olesen RK; Propper D; Bridgewater J; Azzabi A; Farrugia D; Webb A; Cunningham D; Hickish T; Weaver A; Gollins S; Wasan HS; Paul J
    Lancet Oncol; 2018 Apr; 19(4):562-578. PubMed ID: 29611518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: a pooled analysis of three phase III studies.
    Ramanathan RK; Rothenberg ML; de Gramont A; Tournigand C; Goldberg RM; Gupta S; André T
    Ann Oncol; 2010 Apr; 21(4):754-758. PubMed ID: 19887466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Hosokawa A; Ogawa K; Ando T; Suzuki N; Ueda A; Kajiura S; Kobayashi Y; Tsukioka Y; Horikawa N; Yabushita K; Fukuoka J; Sugiyama T
    Anticancer Res; 2012 Jul; 32(7):2545-50. PubMed ID: 22753712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Investigating the incidence of injection-site reactions associated with administration of oxaliplatin into a peripheral vein and management local adverse reactions].
    Hibi S; Tatematsu M; Nishio S; Miyatani M; Tosaki K; Ohara M; Maeda T; Tomita N; Kawai M; Ina K; Oishi K; Muro K
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1447-52. PubMed ID: 21918339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic efficacy of ninjin'yoeito for oxaliplatin-induced cumulative peripheral neuropathy in patients with colorectal cancer receiving postoperative adjuvant chemotherapy: a randomized, open-label, phase 2 trial (HOPE-2).
    Motoo Y; Tomita Y; Fujita H
    Int J Clin Oncol; 2020 Jun; 25(6):1123-1129. PubMed ID: 32232692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of oxaliplatin-induced peripheral neuropathy by a polyamine-reduced diet-NEUROXAPOL: protocol of a prospective, randomised, controlled, single-blind and monocentric trial.
    Balayssac D; Ferrier J; Pereira B; Gillet B; Pétorin C; Vein J; Libert F; Eschalier A; Pezet D
    BMJ Open; 2015 Apr; 5(4):e007479. PubMed ID: 25833669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.
    de Andrade DC; Jacobsen Teixeira M; Galhardoni R; Ferreira KSL; Braz Mileno P; Scisci N; Zandonai A; Teixeira WGJ; Saragiotto DF; Silva V; Raicher I; Cury RG; Macarenco R; Otto Heise C; Wilson Iervolino Brotto M; Andrade de Mello A; Zini Megale M; Henrique Curti Dourado L; Mendes Bahia L; Lilian Rodrigues A; Parravano D; Tizue Fukushima J; Lefaucheur JP; Bouhassira D; Sobroza E; Riechelmann RP; Hoff PM; ; Valério da Silva F; Chile T; Dale CS; Nebuloni D; Senna L; Brentani H; Pagano RL; de Souza ÂM
    Oncologist; 2017 Oct; 22(10):1154-e105. PubMed ID: 28652279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
    Cathomas R; Köberle D; Ruhstaller T; Mayer G; Räss A; Mey U; von Moos R
    Support Care Cancer; 2010 Oct; 18(10):1263-70. PubMed ID: 19756772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
    Bondad N; Boostani R; Barri A; Elyasi S; Allahyari A
    J Oncol Pharm Pract; 2020 Oct; 26(7):1575-1582. PubMed ID: 32063109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
    Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
    Yoshida Y; Hoshino S; Aisu N; Naito M; Tanimura S; Mogi A; Tanaka T; Hirata K; Tamura K; Yamashita Y
    Int J Clin Oncol; 2015 Apr; 20(2):332-7. PubMed ID: 24811333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
    Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
    Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
    Suenaga M; Mizunuma N; Shinozaki E; Matsusaka S; Chin K; Muto T; Konishi F; Hatake K
    J Support Oncol; 2008; 6(8):373-8. PubMed ID: 19149322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community.
    Protásio BM; Matutino A; Lage LV; Santana I; Ramos R; Sabbaga J; Capareli F; Saragiotto D; Riechelmann R; Hoff PM
    Clin Colorectal Cancer; 2017 Mar; 16(1):65-72. PubMed ID: 27515842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
    Vincenzi B; Frezza AM; Schiavon G; Spoto C; Silvestris N; Addeo R; Catalano V; Graziano F; Santini D; Tonini G
    Support Care Cancer; 2013 May; 21(5):1313-9. PubMed ID: 23196819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
    de Gramont A; Van Cutsem E; Schmoll HJ; Tabernero J; Clarke S; Moore MJ; Cunningham D; Cartwright TH; Hecht JR; Rivera F; Im SA; Bodoky G; Salazar R; Maindrault-Goebel F; Shacham-Shmueli E; Bajetta E; Makrutzki M; Shang A; André T; Hoff PM
    Lancet Oncol; 2012 Dec; 13(12):1225-33. PubMed ID: 23168362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.
    Watanabe D; Fujii H; Yamada Y; Iihara H; Ishihara T; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
    Anticancer Res; 2020 Jan; 40(1):299-304. PubMed ID: 31892580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
    Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
    Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.